Health Care · Pharmaceutical Preparations · Nasdaq · CIK 1421876 · no price history on file
Price series unavailable — No prices available for LKFT in [1900-01-01, 2026-07-30]. This symbol may require bring-your-own-key (BYOK) data.
| Days to cover16.1d |
Short interest is FINRA semi-monthly, settlement 2026-07-15.
LKFT is not in the screener universe.
No return windows available for LKFT.
No risk analytics available for LKFT.
| Manager | Shares | Value | % sh out | QoQ |
|---|---|---|---|---|
| GILEAD SCIENCES, INC. | 16.7M | $501M | — | +0.0% |
| TANG CAPITAL MANAGEMENT LLC | 3.8M | $114M | — | −3.4% |
| Madison Avenue Partners, LP | 2.5M | $74M | — | +11.4% |
| EcoR1 Capital, LLC | 1.7M | $50M | — | +0.0% |
| Prosight Management, LP | 1.6M | $47M | — | +44.3% |
| AMERIPRISE FINANCIAL INC | 1.4M | $43M | — | −1.8% |
| DME Capital Management, LP | 482,746 | $14M | — | +0.0% |
| SEGALL BRYANT & HAMILL, LLC | 426,412 | $13M | — | −4.8% |
Reported 13F long positions as filed for 2026-Q1 (change vs 2025-Q4). 13F covers US-listed long equity only — the sum is a LOWER BOUND on institutional ownership, never a total. % of shares outstanding not shown: no SEC cover-page share count falls within 120 days of the 2026-Q1 quarter end, so any percentage would rest on a count that cannot speak for this quarter. Holder share counts are shown as filed.
No reported quarters on file for LKFT.
